98%
921
2 minutes
20
The abilities of the new Vitek 2 AST-YS08 (YS08) and Sensititre YeastOne (SYO) systems to detect the resistances of isolates to azoles and echinocandins were evaluated. In total, 292 isolates, including 28 (6 Erg11 and 2 Fks mutants), 57 (26 Erg11 mutants), 24 (10 Erg11 and 1 Fks mutants), and 183 (39 Pdr1 and 13 Fks mutants) isolates, were tested. The categorical agreements (CAs) between the Clinical and Laboratory Standards Institute (CLSI) method and YS08 fluconazole MICs obtained using clinical breakpoints were 92.4% (), 96.5% (), and 87.0% (), and the CAs between the CLSI and SYO MICs were 92.3% (), 77.2% (), 100% (), and 98.9% (). For , the CAs with the CLSI micafungin MICs were 92.4% and 55.5% for the YS08 micafungin and caspofungin MICs, respectively; they were 100%, 95.6%, and 98.9% for the SYO micafungin, caspofungin, and anidulafungin MICs, respectively. YS08 does not provide fluconazole data for ; the CA with the CLSI fluconazole MIC was 97.8% for the YS08 voriconazole MIC, using an epidemiological cutoff value (ECV) of 0.5 μg/ml. Increased CAs with the CLSI MIC were observed for the YS08 MIC using CLSI ECVs (for fluconazole and , 100%; for micafungin and , 98.9%) and for the SYO MIC using method-specific ECVs (for fluconazole and , 91.2%; for caspofungin and , 98.9%). Therefore, the YS08 and SYO systems may have different abilities to detect mechanisms of azole and echinocandin resistance in four species; the use of method-specific ECVs may improve the performance of both systems.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577149 | PMC |
http://dx.doi.org/10.1128/AAC.00740-20 | DOI Listing |
J Antimicrob Chemother
June 2025
University of California Davis Medical Center, Sacramento, CA, USA.
The increasing prevalence of candidemia and invasive candidiasis infections caused by Candida auris represents a global health risk. Such infections are difficult to treat as they are often multidrug-resistant and are linked to high rates of mortality. Rezafungin is a second-generation echinocandin with antifungal activity against a range of Candida species, including wild type, and azole- and some echinocandin-resistant isolates.
View Article and Find Full Text PDFMycoses
November 2024
Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain.
Background: Previous studies correlated Sensititre YeastOne and gradient diffusion plastic strips with standard procedures for the detection of echinocandin-resistant C. glabrata isolates. However, these studies were limited by the low number of resistant isolates studied; the inclusion of sufficient numbers of mutant isolates is essential to test the procedures' capacity to detect resistance.
View Article and Find Full Text PDFEmerg Microbes Infect
December 2024
National Clinical Research Center for Laboratory Medicine, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Department of Laboratory Medicine, the First Hospital of China Medical University, Shenyang, People's Republic of China.
Introduction: Drug resistance to echinocandins, first-line drugs used to treat infection, is rapidly emerging. However, the accumulation of mutations in genes other than 1 (before an isolate develops to resistance via 1 mutations), remains poorly understood. Four clinical cases and 29 isolates associated with the incremental process of echinocandin resistance were collected and analyzed using antifungal drug susceptibility testing and genome sequencing to assess the evolution of echinocandin resistance.
View Article and Find Full Text PDFJ Fungi (Basel)
March 2024
Clinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.
J Antimicrob Chemother
June 2023
Clinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Rimini 1, Haidari 12462 Athens, Greece.